Welcome to our dedicated page for Ashland news (Ticker: ASH), a resource for investors and traders seeking the latest updates and insights on Ashland stock.
Ashland Inc. (NYSE: ASH) is a global leader in specialty chemicals and advanced additives serving industries from pharmaceuticals to sustainable construction. This page provides investors and professionals with essential updates on corporate developments, financial results, and market innovations.
Discover official press releases alongside curated analysis of Ashland's strategic initiatives in life sciences, personal care ingredients, and industrial solutions. Our repository includes updates on product launches, sustainability efforts, and operational milestones that shape the company's trajectory.
Key content categories include quarterly earnings reports, merger and acquisition activity, leadership changes, and technological breakthroughs in specialty chemicals. All materials are sourced from verified channels to ensure accuracy and relevance for decision-makers.
Bookmark this page for streamlined access to Ashland's evolving story. Check regularly for new developments that demonstrate the company's commitment to solving complex material science challenges through innovation.
Ashland Inc. (NYSE: ASH) announced plans to release its second-quarter earnings on May 2, 2023, at 5 p.m. ET. The company will host a live webcast for analysts on May 3, 2023, at 9 a.m. ET, featuring an executive summary and detailed remarks. Participants in the event include CEO Guillermo Novo, CFO Kevin Willis, and Director of Investor Relations Seth Mrozek. A slide presentation will be available on Ashland's Investor Relations website. The archived version of the webcast and supporting materials will be accessible for 12 months after the event. Ashland is a global provider of additives and specialty ingredients, with a focus on ESG practices, serving numerous markets including food and beverage and pharmaceuticals.
Ashland Inc. (NYSE: ASH) reported Q1 2023 sales of $525 million, reflecting a 3% increase year-over-year, primarily driven by strong demand for pharmaceutical ingredients. Net income decreased to $40 million, or $0.73 per diluted share, while income from continuing operations rose to $42 million, or $0.76 per diluted share. Adjusted EBITDA reached $108 million but faced pressures from foreign currency impacts and planned maintenance costs. Operating cash flow was negative $29 million, leading to ongoing free cash flow also remaining negative at $21 million. The company maintains its fiscal year 2023 sales guidance of $2.5 billion to $2.7 billion.
FAQ
What is the current stock price of Ashland (ASH)?
What is the market cap of Ashland (ASH)?
